Skip to main content
Stock Info
NASDAQTHRX

Investor Relations

Stock
Information
Financial
Filings

Company Profile

Theseus Pharmaceuticals is passionately committed to improving the lives of cancer patients by working to outsmart cancer resistance. Led by a team of targeted oncology pioneers with a proven track record developing and commercializing cancer therapeutics, the Company is developing next-generation tyrosine kinase inhibitors (TKIs): “pan-variant” targeted therapies that address all major drug resistant mutations. Theseus believes a pan-variant approach is the most effective way to address cancer resistance.

The Company’s lead program, THE-630, is a pan-variant KIT inhibitor for patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor to address C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

Recent News
Oct 6, 2021

Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery...

Jun 10, 2021

Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, today announced the appointment of Kathy Yi,...

View All

Investor Tools
IR Contacts

Theseus Pharmaceuticals
857-400-9491 
IR@theseusrx.com